Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Friday 15 April, 2011

Summit Corporation PLC

Notice of AGM






Summit Corporation plc
("Summit" or "the Company")


NOTICE OF ANNUAL GENERAL MEETING

Oxford, UK, 15 April 2011, Summit (AIM: SUMM), a UK drug discovery Company with
a portfolio of drug programmes and an innovative SeglinTM technology platform
for the discovery of new medicines announces that its Annual Report and Accounts
for the year ended 31 January 2011 ('Annual Report') together with the Notice of
Annual General Meeting ('AGM') have been posted to shareholders.  Copies of the
Annual Report will shortly be available on the Company's
website,www.summitplc.com.

The AGM will be held at 10:00am on Thursday 19 May 2011 at Milton Park
Innovation Centre, 99 Milton Park, Abingdon, Oxfordshire, OX14 4RY.

                                    - END -

For more information, please contact:

 Summit

 Barry Price, PhD,

 Richard Pye, PhD                             Tel: +44 (0)1235 443 939



 Singer Capital Markets (Nominated Adviser)

 Shaun Dobson / Claes Spång                   Tel: +44 (0)20 3205 7500



 Peckwater PR

 Tarquin Edwards                              Tel: +44 (0)7879 458 364
                                              tarquin.edwards@peckwaterpr.co.uk



Notes to Editors

About Summit
Summit is an Oxford, UK based drug discovery company with an innovative
technology platform called Seglins(TM) for the discovery of new medicines, a
portfolio of drug programme assets and a commercial strategy of signing multiple
early-stage deals.

Seglin(TM) technology is using new chemistry to access biological drug targets
that cannot be exploited by conventional drug discovery approaches.  Summit's
internal research is currently focussed in the high-value therapy areas and the
Company will further exploit the technology's wider potential through strategic
alliances.  Summit's programme portfolio consists of a number of drug programmes
targeting high-value areas of unmet medical need including Duchenne Muscular
Dystrophy and C. difficile infection.

Summit's commercial strategy focuses on signing multiple early-stage drug
programme and technology platform deals that generate upfront cash, remove
development costs from the Company, and retain valuable upside potential.

Summit is listed on the AIM market of the London Stock Exchange and trades under
the ticker symbol SUMM.  Further information is available atwww.summitplc.com.







This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Summit Corporation PLC via Thomson Reuters ONE

[HUG#1505685]